Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jaliffe GG, Cicin I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, André V, Harbeck N, Martin M, monarchE Committee Members

Open source

DOI: 10.1016/s1470-2045(22)00694-5
Published: 2023 Jan
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-22-00694-5,
  title = {Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.},
  author = {Johnston SRD and Toi M and O'Shaughnessy J and Rastogi P and Campone M and Neven P and Huang CS and Huober J and Jaliffe GG and Cicin I and Tolaney SM and Goetz MP and Rugo HS and Senkus E and Testa L and Del Mastro L and Shimizu C and Wei R and Shahir A and Munoz M and San Antonio B and André V and Harbeck N and Martin M and monarchE Committee Members},
  year = {2023},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(22)00694-5},
  url = {https://doi.org/10.1016/s1470-2045(22)00694-5}
}

RIS

TY  - JOUR
TI  - Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
AU  - Johnston SRD
AU  - Toi M
AU  - O'Shaughnessy J
AU  - Rastogi P
AU  - Campone M
AU  - Neven P
AU  - Huang CS
AU  - Huober J
AU  - Jaliffe GG
AU  - Cicin I
AU  - Tolaney SM
AU  - Goetz MP
AU  - Rugo HS
AU  - Senkus E
AU  - Testa L
AU  - Del Mastro L
AU  - Shimizu C
AU  - Wei R
AU  - Shahir A
AU  - Munoz M
AU  - San Antonio B
AU  - André V
AU  - Harbeck N
AU  - Martin M
AU  - monarchE Committee Members
PY  - 2023
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(22)00694-5
UR  - https://doi.org/10.1016/s1470-2045(22)00694-5
ER  -

APA

SRD, J., M, T., J, O., P, R., M, C., P, N., CS, H., J, H., GG, J., I, C., SM, T., MP, G., HS, R., E, S., L, T., L, D. M., C, S., R, W., A, S., M, M., B, S. A., V, A., N, H., M, M., & Members, M. C. (2023). Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(22)00694-5

Source records

pubmed · retrieved 2026-09-27T08:17:16.819Z